Cann Group Ltd (ASX: CAN) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Cann Group Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $96.01 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 349.12 million
Earnings per share -0.098
Dividend per share N/A
Year To Date Return -3.45%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Cann Group Ltd (ASX: CAN)
Latest News

⏸️ Investing

Pot stock Cannpal Animal Therapeutics Ltd hits the ASX boards

Cannpal Animal Therapeutics Ltd (ASX: CP1) shares have not had the best start to life on the Australian share market …

Read more »

⏸️ Investing

Why these 4 ASX shares are ending the week in the red

In afternoon trade the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) is on course to make it three successive days of …

Read more »

Down chart
⏸️ Investing

Why these 4 ASX shares sank lower today

In afternoon trade the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) has given back some of its early gains but still …

Read more »

disappointed, angry
⏸️ Investing

Why these 4 ASX shares are ending the week in the red

At long last the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) is having an especially positive day. In afternoon trade the …

Read more »

medical marijuana
⏸️ Investing

Australian pot stocks: August update

One of the most talked about areas of the market this year has been the fledgling medicinal cannabis industry. But …

Read more »

Marijuana Pots
⏸️ Investing

Why the Cann Group Ltd share price just stormed higher

Although the Cann Group Ltd (ASX: CAN) share price faded as the day went on and ended the day lower, …

Read more »

medical marijuana
⏸️ Investing

Why the Cann Group Ltd share price rocketed higher today

The Cann Group Ltd (ASX: CAN) share price has been amongst the biggest movers on the market again today. In …

Read more »

⏸️ Investing

Why Cann Group Ltd just hit a record high

Shares in medicinal cannabis hopeful Cann Group Ltd (ASX: CAN) smoked the ASX today to climb 15% to a record …

Read more »

CAN ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

About Cann Group Ltd

Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the company; the development and manufacture (via third party arrangements) of finished product formulations; and the pursuit and execution of various supply and offtake agreements with third parties.

CAN Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
25 Jan 2022 $0.28 $0.01 3.64% 1,634,400 $0.29 $0.29 $0.28
24 Jan 2022 $0.28 $-0.01 -3.51% 1,966,218 $0.28 $0.29 $0.28
21 Jan 2022 $0.29 $0.00 0.00% 472,787 $0.29 $0.29 $0.28
20 Jan 2022 $0.29 $0.00 0.00% 355,014 $0.29 $0.29 $0.28
19 Jan 2022 $0.29 $0.00 0.00% 512,633 $0.29 $0.29 $0.28
18 Jan 2022 $0.29 $-0.01 -3.45% 97,057 $0.29 $0.29 $0.29
17 Jan 2022 $0.29 $0.01 3.51% 114,761 $0.29 $0.29 $0.29
14 Jan 2022 $0.29 $-0.01 -3.45% 437,090 $0.29 $0.29 $0.29
13 Jan 2022 $0.29 $0.00 0.00% 561,780 $0.29 $0.29 $0.29
12 Jan 2022 $0.29 $0.00 0.00% 174,412 $0.29 $0.30 $0.29
11 Jan 2022 $0.29 $0.00 0.00% 187,362 $0.29 $0.30 $0.29
10 Jan 2022 $0.29 $-0.01 -3.39% 207,543 $0.30 $0.30 $0.29
07 Jan 2022 $0.30 $0.01 3.51% 543,378 $0.29 $0.30 $0.29
06 Jan 2022 $0.29 $0.00 0.00% 219,333 $0.29 $0.29 $0.29
05 Jan 2022 $0.29 $0.00 0.00% 281,585 $0.29 $0.29 $0.29
04 Jan 2022 $0.29 $0.00 0.00% 394,331 $0.29 $0.30 $0.29
31 Dec 2021 $0.29 $0.00 0.00% 111,869 $0.30 $0.30 $0.29
30 Dec 2021 $0.29 $-0.01 -3.39% 44,214 $0.30 $0.30 $0.29

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
07 Sep 2021 Douglas (Doug) Rathbone Buy 363 $100,000
07 Sep 2021 Allan McCallum Buy 545 $150,000
07 Sep 2021 John Sharman Buy 72 $20,000
07 Sep 2021 Philip Jacobsen Buy 2 $750,000
07 Sep 2021 Geoffrey(Geoff) Pearce Buy 181 $50,000

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Douglas (Doug) John Rathbone Non-Executive Director Mar 2015
Mr Rathbone is an experienced public company director and is a former Board member of the FERNZ Corporation and the CSIRO. He is Chairman of the Rathbone Wine Group and Chairman since 1 April 2018, Go Resources, Queenscliff Harbour Pty Ltd and AgBiTech. He is also a former member of the RABO Bank Advisory Board, an Honorary Life Governor of the Royal Children's Hospital and a former Director of the Burnett Centre for Medical Research. Doug brings to the Board experienced management and corporate governance skills together with a passion to grow the business having successfully transformed Nufarm to become one of the world's leading crop protection and seed companies with an global footprint. He is also member of Risk and Capital Committees.
Mr Allan D McCallum Non-Executive ChairmanNon-Executive Director Jan 2015
Mr McCallum has broad experience as a public company director in agribusiness and healthcare and have experience in strategy development and implementation and mergers and acquisitions. He is also member of Risk Committee and chairman of Capital Committees.
Mr John Stewart Sharman Non-Executive Director Apr 2021
Mr Sharman has an international business experience as a Managing Director, CEO, CFO and non-executive director with public and private companies, including several ASX listed entities. He has an understanding of the medical manufacturing industry as well as the pharmaceutical and nutraceutical sectors. He has led businesses with operations in Australia, the UK, Europe, Asia and the USA, building distribution, sales, marketing and manufacturing networks both locally and internationally. Mr Sharman is currently the CEO of Universal Biosensors Inc (ASX:UBI). Prior to that he served 10 years as CEO of Medical Developments International (ASX:MVP). Previous roles included Managing Director of CVC Venture Managers (private equity managers), Managing Director of Vita Life Sciences (ASX:VSC) and Cyclopharm (ASX:CYC), as well as roles at PriceWaterhouseCoopers, National Australia Bank and KPMG in both London and Melbourne.
Ms Jennifer (Jenni) Pilcher Non-Executive Director Sep 2020
Ms Pilcher has senior executive experience in the medical and biotechnology sectors and is currently the Chief Financial Officer and Company Secretary of Mach7 Technologies (ASX:M7T). She has previously held executive roles with Alchemia Limited (ASX:ACL) and Mesoblast Limited (ASX:MSB).
Mr Geoffrey(Geoff) Ronald Pearce Non-Executive Director Apr 2016
Mr Pearce is a entrepreneur and businessman with more than 40 years experience in the personal care industry. He established and owned Scental Pacific Pty Ltd and grew the business to become Victoria's largest manufacturer of personal care products before selling it to the Smorgon Family. He later built a contract manufacturing business, Beautiworx Australia Pty Ltd, which was also sold. Geoff currently owns The Continental Group, which supplies pharmaceutical packaging and raw materials and has developed alliances with some of the world's leading herbal extract manufacturers. He has experience in areas including manufacturing, procurement, distribution and regulatory affairs. He is also member of Risk and Capital Committees.
Mr Peter Crock Chief Executive Officer
Ms Geraldine Farrell Company Secretary Dec 2019
Peter Crock Chief Executive Officer
Greg Bullock Chief Financial Officer
Shane Duncan Chief Operating Officer
Geoff Aldred Chief Projects & Information Officer
Geraldine Farrell Company Secretary

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
National Nominees Limited 9,202,765 2.96%
Mr Philip Jacobsen & Mrs Maxine Jacobsen 6,319,518 2.03%
Flag Capital Pty Ltd 6,114,881 1.97%
Mullacam Pty Ltd 5,155,000 1.66%
Supernova Fund Pty Ltd 3,590,909 1.16%
Citicorp Nominees Pty Limited 2,987,457 0.96%
HSBC Custody Nominees (Australia) Limited 2,703,456 0.87%
Harvest One Cannabis Inc 2,248,615 0.72%
Invia Custodian Pty Limited 2,225,395 0.72%
Hardmail Pty Ltd 1,931,852 0.62%
Ms Samira Oliveira Vescovi 1,800,000 0.58%
Commonwealth Scientific And 1,675,533 0.54%
Industrial Research Organisation 1,525,000 0.49%
BNP Paribas Nominees Pty Ltd 1,350,000 0.43%
Australian Businesspoint Pty Ltd 1,250,000 0.40%
Mr Raymond Thomas Hobson & Mrs Rhonda Ellen Hobson 1,200,000 0.39%
Ms Lifang Hao 1,200,000 0.39%
Egea Pty Ltd 1,149,050 0.37%
Estelville Nominees Proprietary Limited 1,127,148 0.36%
BNP Paribas Nominees Pty Ltd Six Sis Ltd 1,062,000 0.34%